Das Medizinportal
Menü

Literatur:

State of the Art: Therapie des Schilddrüsenkarzinoms

Andreas K. Buck1, Christina Blümel1, Johannes Biko1, Stefanie Hahner2 , Martin Gasser3, 1Klinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Würzburg, Schwerpunkt Endokrinologie, 2Medizinische Klinik und Poliklinik I, Universitätsklinikum Würzburg, 3Chirurgische Klinik I, Universitätsklinikum Würzburg (Seite 9-12)

 

  1. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009; 19:1167-1214.
  2. Dralle H, Musholt TJ, Schabram J, Steinmüller T, Frilling A, Simon D, Goretzki PE, Niederle B, Scheuba C, Clerici T, Hermann M, Kußmann J, Lorenz K, Nies C, Schabram P, Trupka A, Zielke A, Karges W, Luster M, Schmid KW, Vordermark D, Schmoll HJ, Mühlenberg R, Schober O, Rimmele H, Machens A. German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors. Langenbecks Arch Surg. 2013; 398:347-75.
  3. Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJ, Tennvall J, Bombardieri E; European Association of Nuclear Medicine (EANM). Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008; 35:1941-59.
  4. Pacini F, Ladenson PW, Schlumberger M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab. 2006; 91:926-32.
  5. Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, Nicol A, Clark PM,Farnell K, McCready R, Smellie J, Franklyn JA, John R, Nutting CM, Newbold K, Lemon C, Gerrard G, Abdel-Hamid A, Hardman J, Macias E, Roques T, Whitaker S, Vijayan R, Alvarez P, Beare S, Forsyth S, Kadalayil L, Hackshaw A. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med. 2012; 366:1674-85.
  6. Reiners C, Hänscheid H, Luster M, Lassmann M, Verburg FA. Radioiodine for remnant ablation and therapy of metastatic disease. Nat Rev Endocrinol. 2011; 7:589-95.
  7. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely PE Jr, Vasko VV, Saji M, Rittenberry J, Wei L, Arbogast D, Collamore M, Wright JJ, Grever M, Shah MH. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol. 2009; 27:1675-84.
  8. Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R, Shong YK, Sherman SI, Smit JW, Chung J, Kappeler C, Peña C, Molnár I, Schlumberger MJ; DECISION investigators. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014; 384:319-28.
  9. Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, Rubin J, Sideras K, Morris JC 3rd, McIver B, Burton JK, Webster KP, Bieber C, Traynor AM, Flynn PJ, Goh BC, Tang H, Ivy SP, Erlichman C; Endocrine Malignancies Disease Oriented Group; Mayo Clinic Cancer Center; Mayo Phase 2 Consortium. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol. 2010; 11:962-72. 
  10. Schlumberger M1, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015; 372:621-30.
  11. American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M, Wells SA Jr. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009 Jun;19(6):565-612.
  12. Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012 Jan 10;30(2):134-41.
  13. Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EE, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin B, Sherman SI. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013 Oct 10;31(29):3639-46.
  14. Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, Bauman JE, Martins RG. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010; 16:5260-8. 
  15. Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, Rubin J, Karlin N, Sideras K, Morris JC 3rd, McIver B, Hay I, Fatourechi V, Burton JK, Webster KP, Bieber C, Traynor AM, Flynn PJ, Cher Goh B, Isham CR, Harris P, Erlichman C. A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H. J Clin Endocrinol Metab. 2014;99: 1687-93.
  16. Iten F, Müller B, Schindler C, Rochlitz C, Oertli D, Mäcke HR, Müller-Brand J, Walter MA. Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial.Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6696-702.
  17. Smallridge RC, Ain KB, Asa SL, Bible KC, Brierley JD, Burman KD, Kebebew E, Lee NY, Nikiforov YE, Rosenthal MS, Shah MH, Shaha AR, Tuttle RM; American Thyroid Association Anaplastic Thyroid Cancer Guidelines Taskforce. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2012; 22:1104-39.

Therapie seltener urologischer Tumore

Martin Breuer, Peter Albers, Urologische Universitätsklinik Düsseldorf (Seite 13-15)

 

  1. Sonpavde, G., Pagliaro, L.C., Buonerba, C., Dorff, T.B., Lee, R.J., Di Lorenzo, G. (2013). Penile cancer: current therapy and future directions. Annals of Oncology 24: 1179-1189.
  2. Graafland, N.M., Leijte, Joost A P, Valdés Olmos, Renato A, Hoefnagel, C.A., Teertstra, H.J., Horenblas, S. (2009). Scanning with 18F-FDG-PET/CT for detection of pelvic nodal involvement in inguinal node-positive penile carcinoma. European Urology 56: 339-345.
  3. Pizzocaro, G., Algaba, F., Horenblas, S., Solsona, E., Tana, S., Van Der Poel, Hein, Watkin, N.A. (2010). EAU Penile Cancer Guidelines 2009. European Urology 57: 1002-1012.
  4. Protzel, C., Hakenberg, O. (2013). Das Peniskarzinom - eine Herausforderung für die moderne Uro-Onkologie. Aktuelle Urologie 44: 363-369.
  5. Cowan, N.C. (2012). CT urography for hematuria. Nature Reviews. Urology 9: 218-226.
  6. Rouprêt, M., Babjuk, M., Compérat, E., Zigeuner, R., Sylvester, R., Burger, M., Cowan, N., Böhle, A., Van Rhijn, Bas W.G., Kaasinen, E., Palou, J., Shariat, S.F. (2013). European Guidelines on Upper Tract Urothelial Carcinomas: 2013 Update. European Urology 63: 1059-1071.
  7. Takahashi, N., Glockner, J.F., Hartman, R.P., King, B.F., Leibovich, B.C., Stanley, D.W., Fitz-Gibbon, P.D., Kawashima, A. (2010). Gadolinium enhanced magnetic resonance urography for upper urinary tract malignancy. The Journal of Urology 183: 1330-1365.
  8. Gadzinski, A.J., Roberts, W.W., Faerber, G.J., Wolf, J.S. (2010). Long-term outcomes of nephroureterectomy versus endoscopic management for upper tract urothelial carcinoma. The Journal of Urology 183: 2148-2153.
  9. Giannarini, G., Kessler, T.M., Birkhäuser, F.D., Thalmann, G.N., Studer, U.E. (2011). Antegrade perfusion with bacillus Calmette-Guérin in patients with non-muscle-invasive urothelial carcinoma of the upper urinary tract: who may benefit? European Urology 60: 955-960.
  10. Margulis, V., Shariat, S.F., Matin, S.F., Kamat, A.M., Zigeuner, R., Kikuchi, E., Lotan, Y., Weizer, A., Raman, J.D., Wood, C.G. (2009). Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 115: 1224-1233.
  11. Lughezzani, G., Sun, M., Perrotte, P., Shariat, S.F., Jeldres, C., Budaus, L., Alasker, A., Duclos, A., Widmer, H., Latour, M., Guazzoni, G., Montorsi, F., Karakiewicz, P.I. (2010). Should bladder cuff excision remain the standard of care at nephroureterectomy in patients with urothelial carcinoma of the renal pelvis? A population-based study. European Urology 57: 956-962.
  12. O'Brien, T., Ray, E., Singh, R., Coker, B., Beard, R. (2011). Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial). European Urology 60: 703-710.
  13. Germà-Lluch, J.R., Garcia del Muro, X, Maroto, P., Paz-Ares, L., Arranz, J.A., Gumà, J., Alba, E., Sastre, J., Aparicio, J., Fernández, A., Barnadas, A., Terrassa, J., Sáenz, A., Almenar, D., López-Brea, M., Climent, M.A., Sánchez, M.A., Lasso de la Vega, R, Berenguer, G., Pérez, X. (2002). Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis: the experience of the Spanish Germ-Cell Cancer Group (GG). European Urology 42: 553-62; discussion 562-3.
  14. Klein, E.A. (1993). Tumor markers in testis cancer. The Urologic Clinics of North America 20: 67-73.
  15. Albers, P., Albrecht, W., Algaba, F., Bokemeyer, C., Cohn-Cedermark, G., Fizazi, K., Horwich, A., Laguna, M.P. (2011). EAU guidelines on testicular cancer: 2011 update. European Urology 60: 304-319.

Operative Therapie uteriner Leiomyosarkome und endometrialer Stromatumore: State of the Art

F. Andrei Taran, Andreas D. Hartkopf, Bernhard Krämer, Ralf Rothmund, Eva M. Grischke, Diethelm Wallwiener, Sara Brucker, Department für Frauengesundheit, Universitätsklinik Tübingen (Seite 16-18)

 

  1. Echt G, Jepson J, Steel J, et al., Treatment of uterine sarcomas. Cancer., 1990. 66(1):35-9.
  2. Kapp DS, Shin JY, and Chan JK, Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy. Cancer., 2008. 112(4):820-30.
  3. Giuntoli RL, 2nd, Metzinger DS, DiMarco CS, et al., Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol., 2003. 89(3):460-9.
  4. Taran FA, Weaver AL, Gostout BS, et al., Understanding cellular leiomyomas: a case-control study. Am. 203(2):109.e1-6.
  5. Amant F, Coosemans A, Debiec-Rychter M, et al., Clinical management of uterine sarcomas. Lancet Oncol., 2009. 10(12):1188-98.
  6. Park JY, Park SK, Kim DY, et al., The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma. Gynecol. 122(2):255-9.
  7. Seddon BM and Davda R, Uterine sarcomas--recent progress and future challenges. Eur. 78(1):30-40.
  8. Park JY, Kim DY, Suh DS, et al., Prognostic factors and treatment outcomes of patients with uterine sarcoma: analysis of 127 patients at a single institution, 1989-2007. J Cancer Res Clin Oncol., 2008. 134(12):1277-87.
  9. Giuntoli RL, 2nd, Garrett-Mayer E, Bristow RE, et al., Secondary cytoreduction in the management of recurrent uterine leiomyosarcoma. Gynecol Oncol., 2007. 106(1):82-8.
  10. Rothmund R, Huebner M, Joachim C, Hartkopf A, Fehm T, Bamberg M, Wallwiener M, Brucker S, Taran FA, Klinische Charakteristika, operatives Management und adjuvante Therapie von Patientinnen mit uterinen Leiomyosarkomen: Erfahrungen der letzten 27 Jahre. Geburtshilfe und Frauenheilkd 2011 71(12):1085-1089
  11. World Health Organization classification of tumors. Mesenchamyl tumors and related lesions. In: Tavassoli FA, Devilee P, eds. Pathology and genetics of tumors of the breast and female organs. Lyon (France): IARC Press; 2003, 233-36.
  12. Gadducci A, Cosio S, Romanini A, Genazzani AR. The management of patients with uterine sarcoma: a debated clinical challenge. Crit Rev Oncol Hematol. 2008;65(2):129-42.
  13. Chang KL, Crabtree GS, Lim-Tan SK, Kempson RL, Hendrickson MR. Primary uterine endometrial stromal neoplasms. A clinicopathologic study of 117 cases. Am J Surg Pathol. 1990;14(5):415-38.
  14. García-Martínez E, Egea Prefasi L, García-Donas J, Escolar-Pérez PP, Pastor F, González-Martín A. Current management of uterine sarcomas. Clin Transl Oncol. 2011 May;13(5):307-14.
  15. Yoon A, Park JY, Park JY, Lee YY, Kim TJ, Choi CH, Bae DS, Kim BG, Lee JW, Nam JH. Prognostic factors and outcomes in endometrial stromal sarcoma with the 2009 FIGO staging system: A multicenter review of 114 cases. Gynecol Oncol. 2014;132(1):70-5.
  16. Chu MC, Mor G, Lim C, Zheng W, Parkash V, Schwartz PE. Low-grade endometrial stromal sarcoma: hormonal aspects. Gynecol Oncol. 2003;90(1):170-6.
  17. Li AJ, Giuntoli RL 2nd, Drake R, Byun SY, Rojas F, Barbuto D, Klipfel N, Edmonds P, Miller DS, Karlan BY. Ovarian preservation in stage I low-grade endometrial stromal sarcomas. Obstet Gynecol. 2005;106(6):1304-8.
  18. Amant F, De Knijf A, Van Calster B, Leunen K, Neven P, Berteloot P, Vergote I, Van Huffel S, Moerman P. Clinical study investigating the role of lymphadenectomy, surgical castration and adjuvant hormonal treatment in endometrial stromal sarcoma. Br J Cancer. 2007;97(9):1194-9.
  19. Kim WY, Lee JW, Choi CH, Kang H, Kim TJ, Kim BG, Lee JH, Bae DS. Low-grade endometrial stromal sarcoma: a single center's experience with 22 cases. Int J Gynecol Cancer. 2008;18(5):1084-9.
  20. Chan JK, Kawar NM, Shin JY, Osann K, Chen LM, Powell CB, Kapp DS. Endometrial stromal sarcoma: a population-based analysis. Br J Cancer. 2008;99(8):1210-5.
  21. Shah JP, Bryant CS, Kumar S, Ali-Fehmi R, Malone JM Jr, Morris RT. Lymphadenectomy and ovarian preservation in low-grade endometrial stromal sarcoma. Obstet Gynecol. 2008;112(5):1102-8.
  22. Goff BA, Rice LW, Fleischhacker D, Muntz HG, Falkenberry SS, Nikrui N, Fuller AF Jr. Uterine leiomyosarcoma and endometrial stromal sarcoma: lymph node metastases and sites of recurrence. Gynecol Oncol. 1993;50(1):105-9.

 

 

Therapie gastroenteropankreatischer Neuroendokriner Neoplasien

Steffen Heeg, Volker Brass, Medizinische Klinik II, Gastroenterologie und Hepatologie, Universitätsklinikum  Freiburg (Seite 20-22)

 

  1. Diez M, Teule A, Salazar R. Gastroenteropancreatic neuroendocrine tumors: diagnosis and treatment. Annals of gastroenterology : quarterly publication of the Hellenic Society of Gastroenterology. 2013;26(1):29-36.
  2. Williams ED, Sandler M. The classification of carcinoid tumours. Lancet. 1963;1(7275):238-9.
  3. McKenna LR, Edil BH. Update on pancreatic neuroendocrine tumors. Gland surgery. 2014;3(4):258-75.
  4. Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, Diaz-Perez JA, Martinez Del Prado MP, Alonso Orduna V, et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2010;21(9):1794-803.
  5. Koukouraki S, Strauss LG, Georgoulias V, Schuhmacher J, Haberkorn U, Karkavitsas N, et al. Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. European journal of nuclear medicine and molecular imaging. 2006;33(4):460-6.
  6. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, et al. Gastroenteropancreatic neuroendocrine tumours. The Lancet Oncology. 2008;9(1):61-72.
  7. Fendrich V, Waldmann J, Bartsch DK, Langer P. Surgical management of pancreatic endocrine tumors. Nature reviews Clinical oncology. 2009;6(7):419-28.
  8. Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009;27(28):4656-63.
  9. Fendrich V, Bartsch DK. Surgical treatment of gastrointestinal neuroendocrine tumors. Langenbeck's archives of surgery / Deutsche Gesellschaft fur Chirurgie. 2011;396(3):299-311.
  10. Atwell TD, Charboneau JW, Que FG, Rubin J, Lewis BD, Nagorney DM, et al. Treatment of neuroendocrine cancer metastatic to the liver: the role of ablative techniques. Cardiovascular and interventional radiology. 2005;28(4):409-21.
  11. Arnold R, Trautmann ME, Creutzfeldt W, Benning R, Benning M, Neuhaus C, et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut. 1996;38(3):430-8.
  12. Caplin ME, Pavel M, Cwikla JB, Phan AT, Raderer M, Sedlackova E, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. The New England journal of medicine. 2014;371(3):224-33.
  13. Oberg K. Interferon in the management of neuroendocrine GEP-tumors: a review. Digestion. 2000;62 Suppl 1:92-7.
  14. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. The New England journal of medicine. 2011;364(6):514-23.
  15. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. The New England journal of medicine. 2011;364(6):501-13.
  16. Oberg K, Knigge U, Kwekkeboom D, Perren A, Group EGW. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2012;23 Suppl 7:vii124-30.
  17. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. The New England journal of medicine. 1992;326(8):519-23.
  18. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26(13):2124-30.

Moderne Therapie von Weichteilsarkomen

Peter Reichardt, HELIOS Klinikum Berlin-Buch, Klinik für Interdisziplinäre Onkologie, Sarkomzentrum Berlin-Brandenburg (Seite 24-27)

 

  1.  Mastrangelo G, Coindre JM, Ducimetière F et al. Incidence of soft tissue sarcoma and beyond: a population-based prospective study in 3 European regions. Cancer 2012;21: 5339-5348.
  2. Sobin LH, Gospadarowicz MK, Wittekind C (eds.): UICC: TNM classification of malignant tumors. 7th Edition, John Wiley & Sons, New York 2009.
  3. Antman K, Crowley J, Balcerzak SP et al. An Intergroup phase III randomized study of doxorubicin and dacarbacine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 11 (1993) 1276–1285.
  4. Edmonson JH, Ryan LM, Blum RH et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1 (1993) 1269–1275.
  5. Judson I, Verweij J, Gelderblom H et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol 2014;15: 415-23.
  6. Le Cesne A, Blay J-Y, Judson I et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 2004;23: 576–584.
  7. Garcia-Carbonero R et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.J Clin Oncol. 2004 Apr 15;22(8):1480-90.
  8. Yovine A et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol. 2004 Mar 1;22(5):890-9.
  9. Demetri, G.D., et al., Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol, 2009. 27(25): p. 4188-96.
  10. Maki RG, Wathen JK, Patel SR et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol 25 (2007) 2755–2763.
  11. García-Del-Muro X, López-Pousa A, Maurel J et al. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J Clin Oncol. 2011 Jun 20;29(18):2528-33.
  12. van der Graaf WT, Blay JY, Chawla SP et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012;379: 1879-1886. 
  13. Fata F, O'Reilly E, Ilson D, et al: Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 86:2034-2237, 1999
  14. Schlemmer M, Reichardt P, Verweij J et al. (2008).Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer 44:2433-6
  15. Grosso F et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 2007 Jul;8(7):595-602.
  16. Reichardt P, Lindner T, Pink D, Thuss-Patience PC, Kretzschmar A, Dörken B. Chemotherapy in alveolar soft part sarcomas. What do we know? Eur. J. Cancer. 2003;39(11):1511–1516.
  17. Stacchiotti S, Negri T, Zaffaroni N, et al. Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. Ann Oncol. 2011;22(7):1682-1690.
  18. Pink D, Bertz-Lepel J, Busemann C, Bitz U, Reichardt P. Efficacy of trabectedin in patients with advanced or metastatic alveolar soft-part sarcoma. Onkologie. 2012;35(5):249–252.
  19. Sarcoma Meta-analysis Collaboration (SMAC). Adjuvant chemotherapy for localised resectable soft tissue sarcoma in adults. Cochrane Database Syst Rev. 2000;(4):CD001419.
  20. Pervaiz N, Colterjohn N, Farrokhyar F, et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 2008;113:573–581.
  21. Italiano A, Delva F, Mathoulin-Pelissier S, et al. Effect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft tissue sarcomas: a multivariate analysis of the French Sarcoma Group Database. Ann Oncol 2010;21:2436–2441.
  22. Woll PJ, Reichardt P, Le Cesne A, et al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol 2012;13:1045-1054.
  23. Issels RD, Lindner LH, Verweij J, et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol. 2010;11(6):561–570.
  24. ESMO / European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 Suppl 3:iii102-12.

 

 

 

Literatur Update „Personalisierte Therapie des Lungenkarzinoms“

Martin B. Steins,  Michael Thomas, Internistische Onkologie der Thoraxtumoren, Thoraxklinik am Universitätsklinikum Heidelberg (Seite 41-44)

 

  1. Barlesi F, Bons H, Beau-Faller M et al.: Biomarkers (BM) France: Results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10.000 non-small cell lung cancer (NSCLC) patients (pts). J Clin Oncol 2013, 31 (Suppl): abstract 8000
  2. Arteaga CL: Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol 2009, 29(5 Suppl14): 3-9
  3. Brabender J, Danenberg KD, Metzger R et al.: Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 2001, 7: 1850-1855
  4. Mok TS, Wu YL, Thongprasert S et al.: Gefitinib or carboplatin/paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361: 947-957
  5. Goeckenjan G, Sitter H, Thomas M et al.: Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. Interdisziplinäre S3-Leitlinie der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin und der Deutschen Krebsgesellschaft. Pneumologie 2010, 64 (Suppl.): S23-S155
  6. Zhou C, Wu YL, Chen G et al.: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011, 12: 735-742
  7. Rosell R, Carcereny E, Gervais R et al. on behalf of the Spanish Lung Cancer Group in collaboration with the Groupe Français de Pneumo-Cancérologie and the Associazione Italiana Oncologia Toracica: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13: 239-246
  8. Sequist LV, Yang JC, Yamamoto N et al.: Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013, 31: 3327-3334
  9. Yang JC, Hirsh V, Schuler M et al.: Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013, 31: 3342-3350
  10. Young JCH, Wu CY, Schuler M et al.: Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 2015, EPub ahead of print
  11. Fukuoka M, Wu YL, Thongprasert S et al.: Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011, 29: 2866-2874
  12. Yun CH, Mengwasser KE, Toms AV et al.: The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Nat Acad Sci USA 2008, 105: 2070-2075
  13. Yu HA, Arcila ME, Rekhtman M et al.: Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013, 19: 2240-2247
  14. Janjigian Y, Groen HJ, Horn L et al.: Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. J Clin Oncol 2011, 29 (Suppl): abstract 7525
  15. Sattler M, Reddy MM, Hasina R et al.: The role of the c-Met pathway in lung cancer and the potential for targeted therapy. Ther Adv Med Oncol 2011, 3: 171-184
  16. Shaw AT, Yeap BY, Mino-Kenudson M et al.: Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009, 27: 4247-4253
  17. Camidge DR, Bang YJ, Kwak EL et al.: Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012, 13: 1011-1019
  18. Shaw AT, Kim DW, Nakagawa K et al.: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013, 368: 2385–2394
  19. Solomon BJ, Mok T, Kim DW et al.: First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014, 371: 2167-2177
  20. Katayama R, Khan TM, Benes C et al.: Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci USA 2011, 108: 7535-7540
  21. Shaw AT, Kim DW, Mehra R et al.: Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014, 370: 1189-1197
  22. Cancer Genome Atlas Research Network: Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012, 489: 519-524
  23. Ross JS, Wang K, Elkadi OR et al.: Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer. J Clin Pathol 2014, 67: 772-776